Yale Cancer Center | Strategic Alliance Partners

January 05, 2023

Maryam Lustberg, MD, MPH, discusses the real-world use of ovarian suppression therapy in clinical practice for premenopausal patients with hormone receptor-positive, HER2-positive breast cancer.

December 07, 2022

Trastuzumab deruxtecan demonstrated a 64% reduction in the risk of disease progression or death compared with physician's choice of treatment in patients with advanced HER2-positive unresectable and/or metastatic breast cancer who previously received ado-trastuzumab emtansine.

December 07, 2022

Ian Krop, MD, PhD, discusses findings from the phase 3 DESTINY-Breast02 trial in patients with HER2-positive metastatic breast cancer.

November 09, 2022

Daniel P. Petrylak, MD, highlights the use of checkpoint inhibitors, antibody-drug conjugates, and FGFR inhibitors in urothelial cancer and the current sequencing hurdles in the paradigm.

November 03, 2022

Continued treatment for patients with cancer near end of life delays conversations about goals of care and hospice enrollment, escalates costs, and may adversely affect the quality of care patients receive.

October 28, 2022

Katerina Politi, PhD, discusses drug-tolerant persister cells in patients with cancer.

October 24, 2022

The combination of cediranib and olaparib significantly improved radiographic progression-free survival compared with olaparib monotherapy in patients with metastatic castration-resistant prostate cancer.

September 02, 2022

A dramatic presentation at the 2022 American Society of Clinical Oncology Annual Meeting changed treatment standards seemingly overnight for women with previously treated metastatic HER2-low breast cancer. However, fundamental questions remain.

August 22, 2022

Dr Petrylak discusses current issues with genetic testing and disease management in prostate and bladder cancer, some of the reasons for poor testing rates, and the importance of proper multidisciplinary management during testing and when seeking to mitigate adverse effects.

July 30, 2022

Roy S. Herbst, MD, PhD, discusses the importance of evaluating ways of altering tumor host factors to improve response to immunotherapy in patients with lung cancer.

July 26, 2022

Mario Sznol, MD, explains the evaluation of efficacy and safety when examining the benefits of new immunotherapy combinations in cancer.

June 20, 2022

An analysis by Yale Cancer Center researchers identified accelerated genetic aging in breast tissue adjacent to breast cancer tumors.

June 19, 2022

Sajid A. Khan MD, FACS, FSSO, discusses the rationale of examining disparate outcomes in gastrointestinal tract cancer surgery.

June 17, 2022

Novel combinations with CDK4/6 inhibitors, antibody-drug conjugates, and oral selective estrogen receptor degraders are rapidly changing the treatment paradigm in hormone receptor–positive and HER2-positive breast cancer.

June 15, 2022

Sajid A Khan MD, FACS, FSSO, discusses next steps in examining racial disparities in gastrointestinal tract cancer.

June 10, 2022

Scientists at Yale Cancer Center have found that patients with breast cancer and high levels of insulin in the blood may be responsive to metabolism-targeting treatments, which in turn may improve the effectiveness of subsequent chemotherapy treatments.

June 04, 2022

Patritumab deruxtecan produced encouraging responses in patients with HER3-expressing metastatic breast cancer or metastatic triple negative breast cancer.

June 02, 2022

For the 10th consecutive year, OncLive® is honored to recognize oncology leaders whose innovations have contributed to immeasurable improvements in outcomes for countless patients.

May 28, 2022

Neoadjuvant administration of the antibody drug conjugate enfortumab vedotin-ejfv represents a potential future treatment option for patients with muscle invasive bladder cancer who are ineligible for cisplatin-based chemotherapy.

May 20, 2022

The phase 2 clinical trial of a multi-center study known as the COAST clinical trial has demonstrated improved outcomes using immunotherapy combinations for patients with unresectable stage III non–small cell lung cancer.